Baader Bank Aktiengesellschaft Purchases Shares of 5,032 Insmed, Inc. $INSM

Baader Bank Aktiengesellschaft purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 5,032 shares of the biopharmaceutical company’s stock, valued at approximately $712,000.

A number of other hedge funds have also recently bought and sold shares of INSM. EULAV Asset Management bought a new position in Insmed in the 3rd quarter valued at $12,961,000. Resolute Capital Asset Partners LLC acquired a new position in Insmed during the 2nd quarter worth about $2,748,000. Nisa Investment Advisors LLC grew its holdings in Insmed by 374.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after acquiring an additional 8,261 shares during the last quarter. Keybank National Association OH increased its position in Insmed by 76.7% in the 3rd quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock valued at $2,407,000 after acquiring an additional 7,257 shares in the last quarter. Finally, Calamos Advisors LLC raised its stake in shares of Insmed by 53.4% in the third quarter. Calamos Advisors LLC now owns 35,215 shares of the biopharmaceutical company’s stock worth $5,071,000 after acquiring an additional 12,263 shares during the last quarter.

Insmed Stock Performance

Shares of Insmed stock opened at $148.43 on Thursday. The stock’s fifty day simple moving average is $171.34 and its 200 day simple moving average is $161.28. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $31.66 billion, a PE ratio of -23.98 and a beta of 1.11. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Analyst Ratings Changes

Several research firms recently weighed in on INSM. HC Wainwright dropped their price objective on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Barclays assumed coverage on Insmed in a report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 price objective for the company. Truist Financial set a $205.00 target price on shares of Insmed in a research note on Monday, January 12th. Finally, Jefferies Financial Group set a $269.00 price target on shares of Insmed in a research note on Wednesday, December 10th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $204.24.

Insider Buying and Selling

In other news, CEO William Lewis sold 13,396 shares of Insmed stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $44,512,131.15. The trade was a 4.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 640 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total transaction of $100,012.80. Following the completion of the sale, the insider directly owned 56,397 shares of the company’s stock, valued at $8,813,159.19. This represents a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 258,253 shares of company stock worth $46,281,042. Insiders own 3.00% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.